Tris Pharma, Inc., a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, has entered into a licensing agreement with Braingaze Ltd. and launched its new business, Tris Digital Health, which will focus on the development and commercialization of digital diagnostic and therapeutic products for neurological health conditions.     Tris has secured exclusive rights to develop and commercialize Braingaze’s...